
Agnieszka M Tycinska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1367862/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in Medical Sciences, 2022, 67, 18-22.	2.1	7
2	Impact of COVIDâ€19 pandemic on acute heart failure admissions and mortality: a multicentre study (COVâ€HFâ€SIRIO 6 study). ESC Heart Failure, 2022, 9, 721-728.	3.1	20
3	In-Hospital and One-Year Outcomes of Patients after Early and Late Resuscitated Cardiac Arrest Complicating Acute Myocardial Infarction—Data from a Nationwide Database. Journal of Clinical Medicine, 2022, 11, 609.	2.4	0
4	Predicting survival in out-of-hospital cardiac arrest patients undergoing targeted temperature management: The Polish Hypothermia Registry Risk Score. Cardiology Journal, 2021, 28, 95-100.	1.2	8
5	Bleeding events in Polish cardiology wards: the results of a 2-week survey. Kardiologia Polska, 2021, 79, 327-330.	0.6	0
6	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiology Journal, 2021, 28, 607-614.	1.2	3
7	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	1.2	3
8	Mechanical circulatory support. An expert opinion of the Association of Intensive Cardiac Care and the Association of Cardiovascular Interventions of the Polish Cardiac Society. Kardiologia Polska, 2021, 79, 1399-1410.	0.6	5
9	Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiologia Polska, 2020, 78, 825-834.	0.6	7
10	Effects of the coronavirus disease 2019 pandemic on the number of hospitalizations for myocardial infarction: regional differences. Population analysis of 7 million people. Kardiologia Polska, 2020, 78, 1039-1042.	0.6	8
11	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	1.2	7
12	Altered microRNA dynamics in acute coronary syndrome. Postepy W Kardiologii Interwencyjnej, 2020, 16, 287-293.	0.2	5
13	Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGETâ€1 and TARGETâ€2 studies. European Journal of Heart Failure, 2019, 21, 1079-1087.	7.1	27
14	Insulin-like growth factor-binding protein 7 (IGFBP 7) as a new biomarker in coronary heart disease. Advances in Medical Sciences, 2019, 64, 195-201.	2.1	14
15	Fluid therapy in non-septic, refractory acute decompensated heart failure patients – The cautious role of central venous pressure. Advances in Medical Sciences, 2019, 64, 37-43.	2.1	2
16	The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacological Reports, 2019, 71, 73-81.	3.3	16
17	Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and Section of Cardiovascular Pharmacotherapy of the Polish Cardiac Society in cooperation with specialists in other fields of medicine. Kardiologia Polska, 2019. 77. 1206-1229.	0.6	1
18	Perioperative thrombocytopenia predicts poor outcome in patients undergoing transcatheter aortic valve implantation. Advances in Medical Sciences, 2018, 63, 179-184.	2.1	9

#	Article	IF	CITATIONS
19	Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clinica Chimica Acta, 2018, 487, 48-53.	1.1	11
20	Different manifestations of pulmonary embolism in younger compared to older patients: Clinical presentation, prediction rules and long-term outcomes. Advances in Medical Sciences, 2017, 62, 254-258.	2.1	9
21	The causes of thrombocytopenia after transcatheter aortic valve implantation. Thrombosis Research, 2017, 156, 39-44.	1.7	20
22	Thrombocytopenia associated with TAVI—The summary of possible causes. Advances in Medical Sciences, 2017, 62, 378-382.	2.1	20
23	Evaluation of non-surgical periodontal treatment in patients with a past history of myocardial infarction. Dental and Medical Problems, 2017, 54, 41-47.	2.0	1
24	Predictors of Long-Term Mortality in Patients Hospitalized in an Intensive Cardiac Care Unit. International Heart Journal, 2016, 57, 67-72.	1.0	11
25	Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis, 2016, 246, 309-317.	0.8	49
26	The Role of Different Monocyte Subsets in the Pathogenesis of Atherosclerosis and Acute Coronary Syndromes. Scandinavian Journal of Immunology, 2015, 82, 163-173.	2.7	89
27	sVCAM-1 concentration and carotid IMT values in patients with acute myocardial infarction – Atherosclerotic markers of the presence, progress and prognosis. Advances in Medical Sciences, 2015, 60, 101-106.	2.1	9
28	Parameters influencing in-hospital mortality in patients hospitalized in intensive cardiac care unit: is there an influence of anemia and iron deficiency?. Internal and Emergency Medicine, 2015, 10, 337-344.	2.0	14
29	Anemia in Intensive Cardiac Care Unit patients – An underestimated problem. Advances in Medical Sciences, 2015, 60, 307-314.	2.1	10
30	Radial access during percutaneous interventions in patients with acute coronary syndromes: should we routinely monitor radial artery patency by ultrasonography promptly after the procedure and in long-term observation?. International Journal of Cardiovascular Imaging, 2015, 31, 31-36.	1.5	15
31	Variation in the incidence of pulmonary embolism and related mortality depending on the season and day of the week. Polish Archives of Internal Medicine, 2015, 125, 92-94.	0.4	3
32	Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG). Advances in Medical Sciences, 2014, 59, 245-249.	2.1	9
33	Natural history and risk factors of long-term mortality in acute coronary syndrome patients with cardiogenic shock. Advances in Medical Sciences, 2014, 59, 156-160.	2.1	6
34	Application of polymerase chain reaction tests to dentistry – review of literature. Journal of Stomatology, 2014, 67, 674-681.	0.2	0
35	Effect of on-pump versus off-pump coronary bypass surgery on cardiac function assessed by intraoperative transesophageal echocardiography. Advances in Medical Sciences, 2013, 58, 58-66.	2.1	2
36	Myocardial perfusion and intima-media thickness in patients with subclinical hypothyroidism. Advances in Medical Sciences, 2013, 58, 44-49.	2.1	12

Agnieszka M Tycinska

#	Article	IF	CITATIONS
37	Thrombocytopenia and perioperative complications after stentless Freedom Solo valve implantation. Kardiologia Polska, 2013, 71, 334-340.	0.6	5
38	Apelin in acute myocardial infarction and heart failure induced by ischemia. Clinica Chimica Acta, 2012, 413, 406-410.	1.1	30
39	Adiponectin – An independent marker of coronary artery disease occurrence rather than a degree of its advancement in comparison to the IMT values in peripheral arteries. Clinica Chimica Acta, 2012, 413, 749-752.	1.1	9
40	Blood pressure in relation to neurogenic, inflammatory and endothelial dysfunction biomarkers in patients with treated essential arterial hypertension. Advances in Medical Sciences, 2011, 56, 80-87.	2.1	10
41	Pleiotropic Effects Of Add-On Atorvastatin Therapy During The Treatment Of COPD Patients. , 2011, , .		0
42	Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction. Archives of Medical Science, 2011, 6, 955-962.	0.9	14
43	The significance of anaemia in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Kardiologia Polska, 2011, 69, 33-9.	0.6	11
44	Admission B-type natriuretic peptide level predicts long-term survival in low risk ST-elevation myocardial infarction patients. Kardiologia Polska, 2011, 69, 1008-14.	0.6	2
45	Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart and Vessels, 2010, 25, 363-367.	1.2	33
46	Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients – An open, pilot study. Blood Pressure, 2010, 19, 260-266.	1.5	18
47	The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clinica Chimica Acta, 2010, 411, 2014-2018.	1.1	25
48	Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacological Reports, 2010, 62, 883-890.	3.3	11
49	Diagnostic Biomarkers of Essential Arterial Hypertension The Value of Prostacyclin, Nitric Oxide, Oxidized-LDL, and Peroxide Measurements. International Heart Journal, 2009, 50, 341-351.	1.0	22
50	High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia. Advances in Medical Sciences, 2009, 54, 225-32.	2.1	8
51	Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score. Clinica Chimica Acta, 2007, 382, 106-111.	1.1	11
52	The Benefits of Repeated Measurements of B-type Natriuretic Peptide in Patients With First ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. International Heart Journal, 2006, 47, 843-854.	1.0	4